Loading…
Loading…
ASMB does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ASMB and 80,000+ other tickers.
See exactly how ASMB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ASMB and 80,000+ other tickers.
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including…
LQDT, IA and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 25th, 2026.
IA, ASMB, LQDT, OFG and TGT have been added to the Zacks Rank #1 (Strong Buy) List on August 25th, 2026.
LITE, ONTO and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 21st, 2026.
MCY, ASMB, ONTO, BSET and UNH have been added to the Zacks Rank #1 (Strong Buy) List on August 21st, 2026.
Does Assembly Biosciences (ASMB) have what it takes to be a top stock pick for momentum investors? Let's find out.